PDF herunterladen
Semin intervent Radiol 2010; 27(4): 338-347
DOI: 10.1055/s-0030-1267857
© Thieme Medical Publishers

Correction of Coagulopathy for Percutaneous Interventions

Charles Wiltrout1 , Kimi L. Kondo2
  • 1University of Chicago Medical Center, Chicago, Illinois
  • 2Department of Radiology, University of Colorado Denver, Aurora, Colorado
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. November 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

ABSTRACT

Due to medical illness or pharmacotherapy, patients undergoing percutaneous interventions often have abnormal hemostasis. Its etiology may include alterations in the protein-based coagulation system, thrombocytopenia, deficient platelet function, or mixed deficits such as disseminated intravascular coagulation. In this article, the authors review the basic science of each of these etiologies, as well as their available methods of correction. They also review the evidence and guidelines regarding the assessment and treatment of coagulopathy in image-guided procedures. The periprocedural bleeding risk and the urgency of a given procedure guide the management of abnormal hemostasis in this patient population.

KEYWORDS

Anticoagulation - platelets - coagulopathy - disseminated intravascular coagulation - reversal

REFERENCES

  • 1 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting.  Science. 1964;  145 1310-1312
    CrossrefPubMedGoogle Scholar
  • 2 MacFarlane R G. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier.  Nature. 1964;  202 498-499
    CrossrefPubMedGoogle Scholar
  • 3 Hoffman M, Monroe III D M. A cell-based model of hemostasis.  Thromb Haemost. 2001;  85(6) 958-965
    PubMedGoogle Scholar
  • 4 Douketis J D, Berger P B, Dunn A S, Jaffer A K, Spyropoulos A C, Becker R C. Ansell. The perioperative management of antithrombotic therapy.  Chest. 2008;  133 299S-339S
    CrossrefPubMedGoogle Scholar
  • 5 White R H, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio.  Ann Intern Med. 1995;  122(1) 40-42
    CrossrefPubMedGoogle Scholar
  • 6 Makris M, Watson H G. The management of coumarin-induced over-anticoagulation Annotation.  Br J Haematol. 2001;  114(2) 271-280
    CrossrefPubMedGoogle Scholar
  • 7 Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study.  Arch Intern Med. 2003;  163(20) 2469-2473
    CrossrefPubMedGoogle Scholar
  • 8 Riegert-Johnson D L, Volcheck G W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review.  Ann Allergy Asthma Immunol. 2002;  89(4) 400-406
    CrossrefPubMedGoogle Scholar
  • 9 Dezee K J, Shimeall W T, Douglas K M, Shumway N M, O'malley P G. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.  Arch Intern Med. 2006;  166(4) 391-397
    CrossrefPubMedGoogle Scholar
  • 10 Kaul V V, Munoz S J. Coagulopathy of liver disease.  Curr Treat Options Gastroenterol. 2000;  3(6) 433-438
    CrossrefPubMedGoogle Scholar
  • 11 O'Shaughnessy D F, Atterbury C, Bolton Maggs P British Committee for Standards in Haematology, Blood Transfusion Task Force et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.  Br J Haematol. 2004;  126(1) 11-28
    CrossrefPubMedGoogle Scholar
  • 12 Holland L L, Brooks J P. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results.  Am J Clin Pathol. 2006;  126(1) 133-139
    CrossrefPubMedGoogle Scholar
  • 13 Schulman S, Bijsterveld N R. Anticoagulants and their reversal.  Transfus Med Rev. 2007;  21(1) 37-48
    CrossrefPubMedGoogle Scholar
  • 14 Leissinger C A, Blatt P M, Hoots W K, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.  Am J Hematol. 2008;  83(2) 137-143
    CrossrefPubMedGoogle Scholar
  • 15 Holland L, Warkentin T E, Refaai M, Crowther M A, Johnston M A, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.  Transfusion. 2009;  49(6) 1171-1177
    CrossrefPubMedGoogle Scholar
  • 16 Levi M, Peters M, Büller H R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.  Crit Care Med. 2005;  33(4) 883-890
    CrossrefPubMedGoogle Scholar
  • 17 Deveras R A, Kessler C M. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.  Ann Intern Med. 2002;  137(11) 884-888
    CrossrefPubMedGoogle Scholar
  • 18 Atkison P R, Jardine L, Williams S, Barr R M, Quan D, Wall W. Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy.  Transplant Proc. 2005;  37(2) 1091-1093
    CrossrefPubMedGoogle Scholar
  • 19 Bosch J, Thabut D, Bendtsen F European Study Group on rFVIIa in UGI Haemorrhage et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial.  Gastroenterology. 2004;  127(4) 1123-1130
    CrossrefPubMedGoogle Scholar
  • 20 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356(22) 2301-2311
    CrossrefPubMedGoogle Scholar
  • 21 Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.  Thromb Res. 2007;  119(5) 643-651
    CrossrefPubMedGoogle Scholar
  • 22 Levy J H, Tanaka K A, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists.  Anesthesiology. 2008;  109(5) 918-926
    CrossrefPubMedGoogle Scholar
  • 23 Martin J H, Rosser C J, Linebach R F, McCullough D L, Assimos D G. Are coagulation studies necessary before percutaneous nephrostomy?.  Tech Urol. 2000;  6(3) 205-207
    PubMedGoogle Scholar
  • 24 Fisher N C, Mutimer D J. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit.  Intensive Care Med. 1999;  25(5) 481-485
    CrossrefPubMedGoogle Scholar
  • 25 Stecker M S, Johnson M S, Ying J et al.. Time to hemostasis after traction removal of tunneled cuffed central venous catheters.  J Vasc Interv Radiol. 2007;  18(10) 1232-1239 quiz 1240
    CrossrefPubMedGoogle Scholar
  • 26 Darcy M D, Kanterman R Y, Kleinhoffer M A et al.. Evaluation of coagulation tests as predictors of angiographic bleeding complications.  Radiology. 1996;  198(3) 741-744
    PubMedGoogle Scholar
  • 27 Malloy P C, Grassi C J, Kundu S Standards of Practice Committee with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions.  J Vasc Interv Radiol. 2009;  20(7, Suppl) S240-S249
    CrossrefPubMedGoogle Scholar
  • 28 Hirsh J, Bauer K A, Donati M B, Gould M, Samama M M, Weitz J I. American College of Chest Physicians . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 141S-159S
    CrossrefPubMedGoogle Scholar
  • 29 Levi M. Emergency reversal of antithrombotic treatment.  Intern Emerg Med. 2009;  4(2) 137-145
    CrossrefPubMedGoogle Scholar
  • 30 Howland M A. Antidotes in depth. In: Goldfrank LR, Nelson LS, Howland M, Lewin NA, Flomenbaum NE, Hoffman RS Goldfrank's Toxicologic Emergencies. 8th ed. New York; McGraw-Hill 2006: 907
    Google Scholar
  • 31 Hirsh J, Bauer K A, Donati M B et al.. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6 Suppl) 141S-159S
    CrossrefPubMedGoogle Scholar
  • 32 Massonnet-Castel S, Pelissier E, Bara L et al.. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.  Haemostasis. 1986;  16(2) 139-146
    PubMedGoogle Scholar
  • 33 Vavra K A, Lutz M F, Smythe M A. Recombinant factor VIIa to manage major bleeding from newer parental anticoagulants.  Ann Pharmacother. 2010 Apr;  44(4) 718-726
    CrossrefPubMedGoogle Scholar
  • 34 Bijsterveld N R, Moons A H, Boekholdt S M et al.. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.  Circulation. 2002;  106(20) 2550-2554
    CrossrefPubMedGoogle Scholar
  • 35 Haas B, Trerotola S, Itkin M et al.. Abstract No. 89: Tunneled central venous catheter insertion in patients with coagulopathy and thrombocytopenia.  J Vasc Interv Radiol. 2009;  20(2) S35-S36
    PubMedGoogle Scholar
  • 36 Ray Jr C E, Shenoy S S. Patients with thrombocytopenia: outcome of radiologic placement of central venous access devices.  Radiology. 1997;  204(1) 97-99
    CrossrefPubMedGoogle Scholar
  • 37 Wallace M J, Narvios A, Lichtiger B et al.. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia.  J Vasc Interv Radiol. 2003;  14(3) 323-327
    CrossrefPubMedGoogle Scholar
  • 38 The Trial to Reduce Alloimmunization to Platelets Study Group . Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.  N Engl J Med. 1997;  337(26) 1861-1869
    CrossrefPubMedGoogle Scholar
  • 39 Heal J M, Blumberg N. Optimizing platelet transfusion therapy.  Blood Rev. 2004;  18(3) 149-165
    CrossrefPubMedGoogle Scholar
  • 40 Favaloro E J. Clinical utility of the PFA-100.  Semin Thromb Hemost. 2008;  34(8) 709-733
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Weiss H J, Baumgartner H R, Tschopp T B, Turitto V T, Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease.  Blood. 1978;  51(2) 267-279
    PubMedGoogle Scholar
  • 42 Lethagen S. Desmopressin – a haemostatic drug: state-of-the-art review.  Eur J Anaesthesiol. 1997;  14 1-9
    PubMedGoogle Scholar
  • 43 Van Dantzig J M, Duren D R, ten Cate J W. Desmopressin and myocardial infarction.  Lancet. 1989;  i 664
    PubMedGoogle Scholar
  • 44 Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP.  N Engl J Med. 1988;  318(2) 121
    PubMedGoogle Scholar
  • 45 Mannucci P M, Carlsson S, Harris A S. Desmopressin, surgery and thrombosis.  Thromb Haemost. 1994;  71(1) 154-155
    PubMedGoogle Scholar
  • 46 Cattaneo M, Harris A S, Strömberg U, Mannucci P M. The effect of desmopressin on reducing blood loss in cardiac surgery—a meta-analysis of double-blind, placebo-controlled trials.  Thromb Haemost. 1995;  74(4) 1064-1070
    PubMedGoogle Scholar
  • 47 Mannucci P M. Hemostatic drugs.  N Engl J Med. 1998;  339(4) 245-253
    CrossrefPubMedGoogle Scholar
  • 48 Toh C H, Dennis M. Disseminated intravascular coagulation: old disease, new hope.  BMJ. 2003;  327(7421) 974-977
    CrossrefPubMedGoogle Scholar
  • 49 Carey M J, Rodgers G M. Disseminated intravascular coagulation: clinical and laboratory aspects.  Am J Hematol. 1998;  59(1) 65-73
    CrossrefPubMedGoogle Scholar
  • 50 Bucur S Z, Hillyer C D. Cryoprecipitate and related blood procducts. In: Hillyer CD, Hillyer KL, Strobl FJ, Jeffries LC, Silberstein LE Handbook of Transfusion Medicine. San Diego; Academic Press 2001: 50-51
    Google Scholar
  • 51 Drummond J C, Petrovich C T, Lane T A. Hemostasis and transfusion medicine. In: Barash PG, et al Clinical Anesthesia. Philadelphia; Lippincott Williams and Wilkins 2009: 403
    Google Scholar

Kimi L KondoD.O. 

Assistant Professor, Department of Radiology, University of Colorado Denver, Mail Stop L954

12401 East 17th Avenue, Room 537, Aurora, CO 80045

eMail: kimi.kondo@ucdenver.edu